{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:48:57Z","timestamp":1790401737778,"version":"4.1.0"},"reference-count":105,"publisher":"Oxford University Press (OUP)","issue":"42","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Tufts Medical Centerfrom the National Institute of Diabetes and Digestive and Kidney Diseases"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic kidney disease (CKD) and cardiovascular disease are tightly interconnected, with common mechanisms that underlie the development and progression of both diseases, recently articulated into the framework of the cardiovascular-kidney-metabolic syndrome. CKD and heart failure commonly coexist in the same individual, with increasing evidence for common therapies in both disease states. It is valuable for patients, clinicians, and regulatory agencies to understand how to best assess CKD progression in patients with heart failure for evaluation of individual patients and as part of an endpoint for outcome trials. Given the relatively short duration of most heart failure outcome trials, early measures of CKD progression prior to the occurrence of clinical events of kidney replacement therapy would be desirable. Such surrogate measures include slowing of the decline in glomerular filtration rate (GFR) decline either computed as annualized mean change in GFR (GFR slope) or time to substantial declines in GFR by specified threshold percentages (40% or 50% GFR decline). Regulatory agencies accept these endpoints for full drug approval which has enabled progress in design and conduct of trials for CKD progression. Application of these endpoints in heart failure outcome trials has the potential for similar progress. However, an immediate reduction in GFR is common following initiation of several of the guideline directed therapy for heart failure. Understanding how to best interpret an immediate GFR reduction vs long term kidney benefit is critical to optimal assessment of endpoint in an outcome trial and in the use of these medications for management of patients with heart failure. Here, the intersection of heart failure and CKD is described, how GFR and its change over time are assessed in both individual patients and in interventional trials, the evidence supporting use of GFR changes as endpoints in CKD progression trials, and the challenges and possible solutions for the use of GFR as endpoint in heart failure outcome trials and for care of individual patients, guided by case studies to inform the discussion.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehaf591","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:50:55Z","timestamp":1753876255000},"page":"4379-4395","source":"Crossref","is-referenced-by-count":8,"title":["Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2820-9482","authenticated-orcid":false,"given":"Lesley A","family":"Inker","sequence":"first","affiliation":[{"name":"Division of Nephrology, Tufts Medical Center , 800 Washington Street, Box #391, Boston 02111, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9276-8380","authenticated-orcid":false,"given":"Brendon L","family":"Neuen","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1860-6302","authenticated-orcid":false,"given":"Wendy","family":"McCallum","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Tufts Medical Center , 800 Washington Street, Box #391, Boston 02111, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-1953","authenticated-orcid":false,"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-7570","authenticated-orcid":false,"given":"Tom","family":"Greene","sequence":"additional","affiliation":[{"name":"Population Health Sciences, University of Utah School of Medicine , Salt Lake City, UT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J L","family":"Heerspink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen , Groningen ,","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"2025110902423101700_ehaf591-B1","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2025110902423101700_ehaf591-B2"},{"key":"2025110902423101700_ehaf591-B3"},{"key":"2025110902423101700_ehaf591-B4"},{"key":"2025110902423101700_ehaf591-B5"},{"key":"2025110902423101700_ehaf591-B6"},{"key":"2025110902423101700_ehaf591-B7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/j.ajkd.2019.08.007","article-title":"Change in estimated GFR and albuminuria as end points in clinical trials: a viewpoint from the FDA","volume":"75","author":"Thompson","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2025110902423101700_ehaf591-B8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1053\/j.ajkd.2022.03.011","article-title":"Clinical trial considerations in developing treatments for early stages of common, chronic kidney diseases: a scientific workshop cosponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"80","author":"Inker","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2025110902423101700_ehaf591-B9","author":"European Medicines Agency"},{"key":"2025110902423101700_ehaf591-B10","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1053\/j.ajkd.2014.09.006","article-title":"GFR decline as an end point in trials of CKD: a viewpoint from the FDA","volume":"64","author":"Thompson","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2025110902423101700_ehaf591-B11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1053\/j.ajkd.2019.07.019","article-title":"Change in albuminuria and estimated GFR as end points for clinical trials in early stages of CKD: a perspective from European regulators","volume":"75","author":"Holtkamp","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2025110902423101700_ehaf591-B12","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/eurheartj\/ehab832","article-title":"Kidney function assessment and endpoint ascertainment in clinical trials","volume":"43","author":"Khan","year":"2022","journal-title":"Eur Heart J"},{"key":"2025110902423101700_ehaf591-B13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41581-019-0191-y","article-title":"Measured and estimated glomerular filtration rate: current status and future directions","volume":"16","author":"Levey","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2025110902423101700_ehaf591-B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2025110902423101700_ehaf591-B15","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1093\/eurheartj\/ehu320","article-title":"Terminology and definition of changes renal function in heart failure","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"2025110902423101700_ehaf591-B16","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2025110902423101700_ehaf591-B17","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.kint.2020.02.010","article-title":"Nomenclature for kidney function and disease: report of a kidney disease: improving global outcomes (KDIGO) consensus conference","volume":"97","author":"Levey","year":"2020","journal-title":"Kidney Int"},{"key":"2025110902423101700_ehaf591-B18","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/mnh.0000000000000647","article-title":"GFR slope as a surrogate endpoint for CKD progression in clinical trials","volume":"29","author":"Inker","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2025110902423101700_ehaf591-B19","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate endpoint for kidney failure","volume":"29","author":"Inker","year":"2023","journal-title":"Nat Med"},{"key":"2025110902423101700_ehaf591-B20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"The Lancet"},{"key":"2025110902423101700_ehaf591-B21","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/S0140-6736(17)30788-2","article-title":"Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy","volume":"390","author":"Levin","year":"2017","journal-title":"Lancet"},{"key":"2025110902423101700_ehaf591-B22","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025110902423101700_ehaf591-B23","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Writing Group for the Chronic Kidney Disease - Prognosis Consortium","year":"2023","journal-title":"JAMA"},{"key":"2025110902423101700_ehaf591-B24","doi-asserted-by":"publisher","first-page":"100727","DOI":"10.1016\/j.xkme.2023.100727","article-title":"Cystatin C as a GFR estimation marker in acute and chronic illness: a systematic review","volume":"5","author":"Adingwupu","year":"2023","journal-title":"Kidney Med"},{"key":"2025110902423101700_ehaf591-B25","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"2025110902423101700_ehaf591-B26","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1681\/asn.0000000000000227","article-title":"CKD-EPI and EKFC GFR estimating equations: performance and other considerations for selecting equations for implementation in adults","volume":"34","author":"Inker","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2025110902423101700_ehaf591-B27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1053\/j.ajkd.2016.09.016","article-title":"Cystatin C versus creatinine for GFR estimation in CKD due to heart failure","volume":"69","author":"Kervella","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2025110902423101700_ehaf591-B28","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1093\/eurheartj\/ehad210","article-title":"Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial","volume":"44","author":"Tolomeo","year":"2023","journal-title":"Eur Heart J"},{"key":"2025110902423101700_ehaf591-B29","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1093\/eurheartj\/ehad284","article-title":"Risk of knowing too much: the tricky case of estimated glomerular filtration rate and treatment decisions in heart failure","volume":"44","author":"Damman","year":"2023","journal-title":"Eur Heart J"},{"key":"2025110902423101700_ehaf591-B30","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1002\/ehf2.13404","article-title":"Serum creatinine and cystatin C-based estimates of glomerular filtration rate are misleading in acute heart failure","volume":"8","author":"Swolinsky","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2025110902423101700_ehaf591-B31","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1136\/heartjnl-2011-300692","article-title":"Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure","volume":"98","author":"Damman","year":"2012","journal-title":"Heart"},{"key":"2025110902423101700_ehaf591-B32","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1053\/j.ajkd.2023.04.002","article-title":"Discordances between creatinine- and cystatin C-based estimated GFR and adverse clinical outcomes in routine clinical practice","volume":"82","author":"Carrero","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"2025110902423101700_ehaf591-B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000520909","article-title":"Heart failure in patients with diabetes and chronic kidney disease: challenges and opportunities","volume":"12","author":"Vijay","year":"2022","journal-title":"Cardiorenal Med"},{"key":"2025110902423101700_ehaf591-B34","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"2025110902423101700_ehaf591-B35","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/ejhf.821","article-title":"Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"19","author":"Lofman","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2025110902423101700_ehaf591-B36","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"2025110902423101700_ehaf591-B37","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1097\/01.CCM.0000297160.48694.90","article-title":"Cytokines and acute heart failure","volume":"36","author":"Chen","year":"2008","journal-title":"Crit Care Med"},{"key":"2025110902423101700_ehaf591-B38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1159\/000452283","article-title":"The central role of endothelial dysfunction in cardiorenal syndrome","volume":"7","author":"Zhang","year":"2017","journal-title":"Cardiorenal Med"},{"key":"2025110902423101700_ehaf591-B39","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1053\/j.ajkd.2011.12.009","article-title":"Longitudinal progression trajectory of GFR among patients with CKD","volume":"59","author":"Li","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2025110902423101700_ehaf591-B40","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrneph.2016.113","article-title":"Heart failure and kidney dysfunction: epidemiology, mechanisms and management","volume":"12","author":"Schefold","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"2025110902423101700_ehaf591-B41","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/ejhf.1697","article-title":"Evaluation of kidney function throughout the heart failure trajectory\u2014a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Mullens","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2025110902423101700_ehaf591-B42","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/ejhf.2018","article-title":"Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the heart failure collaboratory and academic research consortium","volume":"22","author":"Abraham","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2025110902423101700_ehaf591-B43","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1002\/ejhf.1968","article-title":"Acceleration of kidney function decline after incident hospitalization with cardiovascular disease: the Stockholm CREAtinine Measurements (SCREAM) project","volume":"22","author":"Ishigami","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2025110902423101700_ehaf591-B44","doi-asserted-by":"publisher","first-page":"ehad655.1068","DOI":"10.1093\/eurheartj\/ehad655.1068","article-title":"Estimating the extent to which chronic kidney disease mediates the association between metabolic syndrome and heart failure: the Atherosclerosis Risk in Communities (ARIC) study","volume":"44","author":"Koyawala","year":"2023","journal-title":"Eur Heart J"},{"key":"2025110902423101700_ehaf591-B45","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jchf.2024.02.028","article-title":"Chronic kidney disease progression in heart failure: what we know, don't know, and where to next?","volume":"12","author":"Heerspink","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2025110902423101700_ehaf591-B46","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/eurheartj\/ehi696","article-title":"Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis","volume":"27","author":"de Silva","year":"2006","journal-title":"Eur Heart J"},{"key":"2025110902423101700_ehaf591-B47","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1681\/ASN.2019010008","article-title":"Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data","volume":"30","author":"Grams","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2025110902423101700_ehaf591-B48","doi-asserted-by":"publisher","first-page":"e2449998","DOI":"10.1001\/jamanetworkopen.2024.49998","article-title":"The global kidney patient trials network and the CAPTIVATE platform clinical trial design: a trial protocol","volume":"7","author":"Kotwal","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2025110902423101700_ehaf591-B49","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/ndt\/gfz260","article-title":"Chronic kidney disease progression and mortality risk profiles in Germany: results from the chronic kidney disease outcomes and practice patterns study","volume":"35","author":"Reichel","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2025110902423101700_ehaf591-B50","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jchf.2024.01.004","article-title":"Trajectories of kidney function in heart failure over a 15-year follow-up: clinical profiling and mortality","volume":"12","author":"Zamora","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2025110902423101700_ehaf591-B51","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2025110902423101700_ehaf591-B52","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJM199908193410806","article-title":"Hormones and hemodynamics in heart failure","volume":"341","author":"Schrier","year":"1999","journal-title":"N Engl J Med"},{"key":"2025110902423101700_ehaf591-B53","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jacc.2008.05.068","article-title":"Importance of venous congestion for worsening of renal function in advanced decompensated heart failure","volume":"53","author":"Mullens","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2025110902423101700_ehaf591-B54","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jchf.2017.05.006","article-title":"Intrarenal flow alterations during transition from euvolemia to intravascular volume expansion in heart failure patients","volume":"5","author":"Nijst","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2025110902423101700_ehaf591-B55","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1161\/cir.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"2025110902423101700_ehaf591-B56","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1681\/ASN.V1271335","article-title":"Loop diuretic infusion increases thiazide-sensitive Na(+)\/Cl(-)-cotransporter abundance: role of aldosterone","volume":"12","author":"Abdallah","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"2025110902423101700_ehaf591-B57","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2025110902423101700_ehaf591-B58","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.jacc.2023.02.009","article-title":"Variation in renal function following transition to sacubitril\/valsartan in patients with heart failure","volume":"81","author":"Chatur","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025110902423101700_ehaf591-B59","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1001\/jamacardio.2023.4664","article-title":"Decline in estimated glomerular filtration rate after dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized clinical trial","volume":"9","author":"Mc Causland","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2025110902423101700_ehaf591-B60","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacc.2024.11.020","article-title":"Initial decline in glomerular filtration rate with finerenone in HFmrEF\/HFpEF: a prespecified analysis of FINEARTS-HF","volume":"85","author":"Matsumoto","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2025110902423101700_ehaf591-B61","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/ehf2.15049","article-title":"Real-world data on empagliflozin and dapagliflozin use in patients with HEART failure: the RED-HEART study","volume":"12","author":"Kocabas","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2025110902423101700_ehaf591-B62","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/ejhf.2471","article-title":"Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology","volume":"24","author":"Mullens","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2025110902423101700_ehaf591-B63","doi-asserted-by":"publisher","first-page":"1385281","DOI":"10.3389\/fcvm.2024.1385281","article-title":"The management of heart failure in Sweden-the physician's perspective: a survey","volume":"11","author":"Ferrannini","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"2025110902423101700_ehaf591-B64","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/j.jchf.2024.08.002","article-title":"Physician-reported reasons for not initiating guideline-directed medical therapy for heart failure","volume":"12","author":"Greene","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2025110902423101700_ehaf591-B65","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCHEARTFAILURE.111.963413","article-title":"Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function","volume":"5","author":"Metra","year":"2012","journal-title":"Circ Heart Fail"},{"key":"2025110902423101700_ehaf591-B66","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jchf.2020.03.009","article-title":"Acute kidney function declines in the context of decongestion in acute decompensated heart failure","volume":"8","author":"McCallum","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2025110902423101700_ehaf591-B67","doi-asserted-by":"publisher","first-page":"e004644","DOI":"10.1161\/CIRCHEARTFAILURE.117.004644","article-title":"Prognostic significance of creatinine increases during an acute heart failure admission in patients with and without residual congestion","volume":"11","author":"Metra","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2025110902423101700_ehaf591-B68","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.kint.2020.07.013","article-title":"International consensus definitions of clinical trial outcomes for kidney failure: 2020","volume":"98","author":"Levin","year":"2020","journal-title":"Kidney Int"},{"key":"2025110902423101700_ehaf591-B69","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2025110902423101700_ehaf591-B70","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"2025110902423101700_ehaf591-B71","author":"FDA-NIH Biomarker Working Group"},{"key":"2025110902423101700_ehaf591-B72","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2025110902423101700_ehaf591-B73","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1681\/asn.2019010009","article-title":"Performance of GFR slope as a surrogate end point for kidney disease progression in clinical trials: a statistical simulation","volume":"30","author":"Greene","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2025110902423101700_ehaf591-B74","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/asn.2019010007","article-title":"GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2025110902423101700_ehaf591-B75","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1053\/j.ajkd.2014.08.017","article-title":"GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials","volume":"64","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2025110902423101700_ehaf591-B76","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1053\/j.ajkd.2014.08.019","article-title":"Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study","volume":"64","author":"Greene","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2025110902423101700_ehaf591-B77","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1053\/j.ajkd.2021.03.007","article-title":"Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IgA nephropathy: an individual participant meta-analysis","volume":"78","author":"Inker","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2025110902423101700_ehaf591-B78","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1681\/asn.2021070948","article-title":"Acute treatment effects on GFR in randomized clinical trials of kidney disease progression","volume":"33","author":"Neuen","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2025110902423101700_ehaf591-B79","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2025110902423101700_ehaf591-B80","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2025110902423101700_ehaf591-B81","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2025110902423101700_ehaf591-B82","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/ejhf.2635","article-title":"Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure","volume":"24","author":"Vaduganathan","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2025110902423101700_ehaf591-B83","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2025110902423101700_ehaf591-B84","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1097\/HJH.0b013e3280bad9b4","article-title":"Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system","volume":"25","author":"Turnbull","year":"2007","journal-title":"J Hypertens"},{"key":"2025110902423101700_ehaf591-B85","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.clinthera.2009.02.017","article-title":"The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis","volume":"31","author":"Delahoy","year":"2009","journal-title":"Clin Ther"},{"key":"2025110902423101700_ehaf591-B86","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1471-2288-12-27","article-title":"Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES)","volume":"12","author":"Lassere","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"2025110902423101700_ehaf591-B87","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2215\/CJN.0000000000000050","article-title":"Evaluation of variation in the performance of GFR slope as a surrogate end point for kidney failure in clinical trials that differ by severity of CKD","volume":"18","author":"Collier","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025110902423101700_ehaf591-B88","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"key":"2025110902423101700_ehaf591-B89","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.jacc.2023.03.390","article-title":"Efficacy of empagliflozin in patients with heart failure across kidney risk categories","volume":"81","author":"Butler","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025110902423101700_ehaf591-B90","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1056\/NEJMc2118470","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"386","author":"Heerspink","year":"2022","journal-title":"N Engl J Med"},{"key":"2025110902423101700_ehaf591-B91","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1056\/NEJMc2112411","article-title":"Empagliflozin and major renal outcomes in heart failure","volume":"385","author":"Packer","year":"2021","journal-title":"N Engl J Med"},{"key":"2025110902423101700_ehaf591-B92"},{"key":"2025110902423101700_ehaf591-B93","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1002\/sim.8282","article-title":"Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease","volume":"38","author":"Vonesh","year":"2019","journal-title":"Stat Med"},{"key":"2025110902423101700_ehaf591-B94","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/biom.13438","article-title":"Biased estimation with shared parameter models in the presence of competing dropout mechanisms","volume":"78","author":"Vonesh","year":"2022","journal-title":"Biometrics"},{"key":"2025110902423101700_ehaf591-B95","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jama.292.3.344","article-title":"Trends in heart failure incidence and survival in a community-based population","volume":"292","author":"Roger","year":"2004","journal-title":"JAMA"},{"key":"2025110902423101700_ehaf591-B96","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/archinte.167.5.490","article-title":"Long-term survival after heart failure: a contemporary population-based perspective","volume":"167","author":"Goldberg","year":"2007","journal-title":"Arch Intern Med"},{"key":"2025110902423101700_ehaf591-B97","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2025110902423101700_ehaf591-B98"},{"key":"2025110902423101700_ehaf591-B99","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1002\/ejhf.2638","article-title":"Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trial","volume":"24","author":"Chatur","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2025110902423101700_ehaf591-B100","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1053\/j.ajkd.2021.09.026","article-title":"Rates of reversal of volume overload in hospitalized acute heart failure: association with long-term kidney function","volume":"80","author":"McCallum","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2025110902423101700_ehaf591-B101","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.jchf.2024.01.018","article-title":"Dapagliflozin and timing of prior heart failure hospitalization","volume":"12","author":"Butt","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2025110902423101700_ehaf591-B102","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s41581-019-0213-9","article-title":"Strengths and limitations of estimated and measured GFR","volume":"15","author":"Levey","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"2025110902423101700_ehaf591-B103","doi-asserted-by":"publisher","first-page":"100710","DOI":"10.1016\/j.xkme.2023.100710","article-title":"Discordance between creatinine and cystatin C-based eGFR: interpretation according to performance compared to measured GFR","volume":"5","author":"Wang","year":"2023","journal-title":"Kidney Med"},{"key":"2025110902423101700_ehaf591-B104","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.2337\/dc23-0261","article-title":"Effects of tirzepatide versus insulin glargine on cystatin C-based kidney function: a SURPASS-4 post hoc analysis","volume":"46","author":"Heerspink","year":"2023","journal-title":"Diabetes care"},{"key":"2025110902423101700_ehaf591-B105","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1681\/asn.0000000000000243","article-title":"Development and validation of a new hierarchical composite end point for clinical trials of kidney disease progression","volume":"34","author":"Heerspink","year":"2023","journal-title":"J Am Soc Nephrol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/42\/4379\/64208617\/ehaf591.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/42\/4379\/64208617\/ehaf591.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:42:37Z","timestamp":1762674157000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/46\/42\/4379\/8247913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":105,"journal-issue":{"issue":"42","published-online":{"date-parts":[[2025,9,4]]},"published-print":{"date-parts":[[2025,11,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf591","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,7]]},"published":{"date-parts":[[2025,9,4]]}}}